Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.

@article{Kizer2005StrokeRI,
  title={Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.},
  author={Jorge R Kizer and Bj{\"o}rn Dahl{\"o}f and Sverre Erik Kjeldsen and Stevo Julius and Gareth D Beevers and Ulf H de Faire and Frej Y Fyhrquist and Hans Henning Windel\ov Ibsen and Krister J. Kristianson and Ole Lederballe-Pedersen and Lars Lindholm and Markku S Nieminen and Per Omvik and Suzanne Oparil and Hans Wedel and Kristian Wachtell and Jonathan Edelman and Steven Snapinn and Katherine E. Harris and Richard Blyton Devereux},
  journal={Hypertension},
  year={2005},
  volume={45 1},
  pages={46-52}
}
The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol. We conducted secondary analyses in LIFE to determine the extent to which the cerebrovascular benefits of losartan apply to different clinical subgroups and stroke subtypes and to assess the dependence of these benefits on baseline and time… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…